INTRODUCTION
While endocrine therapy has a well-defined role in the treatment of only three forms of cancer, its importance is illustrated by the fact that two of these diseases, carcinoma of the breast and carcinoma of the prostate, are among the most frequent cancers and are leading causes of cancer death in industrialised countries. Taking breast cancer into consideration, endocrine therapy with antioestrogens or oestrogen suppression (by gonadectomy in premenopausal women or use of aromatase inhibitors in postmenopausal women) has been found to cause tumour regression in advanced disease, and also to improve relapse-free and overall survival when used in the adjuvant setting. In prostatic carcinoma, androgen ablation or use of antiandrogens may cause tumour remission in the majority of patients treated for advanced disease.
There are several reasons to focus on different biochemical effects and alternative mechanisms of action in relation to endocrine therapy. Currently, we have a limited understanding of the mechanisms of resistance to endocrine therapy.
While the response rate to first-line hormonal treatment may be about 50-70% in breast cancer patients whose tumours express the oestrogen receptor (ER), and as high as 70-80% in prostatic carcinoma (see Santen et al. 1990 , Santen 1992 for references to the original work), for unknown reasons resistance inevitably develops, usually within 2 years. Nor do we know why at least 50% of breast cancer patients relapsing after an initial response to first-line treatment subsequently respond to second-line hormone therapy (Kvinnsland et al. 1984) . While no response to first-line hormone treatment in breast cancer may be due to the lack of ERs or the presence of a mutant form (Horwitz 1993) , alternative mechanisms are more likely to be involved in the development of acquired resistance, as the lack of cross-resistance to different endocrine drugs like tamoxifen, aromatase inhibitors or progestins confirms drug-specific resistance not associated with gen¬ eral hormone resistance (Murray & Pitt 1982 , Kaye et al. 1982 , Iveson et al. 1993 ). These observations suggest that non-receptor-mediated mechanisms could be involved in the antitumour action of some of these drugs. Alternatively, a drug might promote growth factor stimulation of certain cell clones, over-ruling its antihormone action, and resulting in tumour growth after an initial treatment response.
Recent investigations have shown that treat¬ ment with tamoxifen modulates the expression of growth factors like transforming growth factor-ß (TGF-ß) (Butta et al. 1992) , which is known to inhibit breast cancer cell growth, as well as that of insulin-like growth factor-I (IGF-I) (Colletti et al. 1989 ), a most potent mitogen to breast cancer cells.
There are several reasons to focus on IGF-I in relation to breast cancer in general, and in relation to endocrine treatment in particular. First, most human breast cancers contain receptors for IGF-I.
Secondly, IGF-I has been confirmed to be a most potent mitogen to breast cancer cells in vitro. Thirdly, plasma levels of IGF-I have been found to be modulated by sex steroids (androgens and oestrogens) and by antihormone therapy used in breast cancer patients.
While the evidence linking IGF-I to tumour growth in prostatic cancer so far is limited, IGF-I has been found to stimulate the growth of certain prostatic carcinoma cells in vitro (see later) .
This paper reviews data suggesting a role for IGF-I (and possibly IGF-II) in breast and prostatic (Romagnoli et al. 1993) , and treatment with luteinising hormone-releasing hormone (LHRH) analogues suppresses plasma levels of IGF-I in premenopausal women with breast cancer (Lien et al. 1992) , and in girls with precocious puberty (Mansfield et al. 1988 ). This is consistent with the observation that oestro¬ gens given by the transdermal route to postmenopausal women elevate serum IGF-I levels (Weissberger et 
